scispace - formally typeset
P

Philip C. Calder

Researcher at University of Southampton

Publications -  808
Citations -  70822

Philip C. Calder is an academic researcher from University of Southampton. The author has contributed to research in topics: Polyunsaturated fatty acid & Eicosapentaenoic acid. The author has an hindex of 125, co-authored 747 publications receiving 59110 citations. Previous affiliations of Philip C. Calder include Southampton General Hospital & Radboud University Nijmegen Medical Centre.

Papers
More filters
Journal ArticleDOI

The role of glutamine in the immune system and in intestinal function in catabolic states.

TL;DR: Evidence is accumulating that glutamine becomes essential when catabolic conditions prevail, and provision of exogenous glutamine has had beneficial effects in humans and animals, particularly in improving intestinal function.
Journal ArticleDOI

Immune factors and fatty acid composition in human milk from river/lake, coastal and inland regions of China

TL;DR: A higher breast milk DHA and AA concentration is associated with higher concentrations of immune factors in breast milk, suggesting a role for these fatty acids in promoting gastrointestinal and immune maturation of the infant.
Journal ArticleDOI

Influence of different intravenous lipid emulsions on fatty acid status and laboratory and clinical outcomes in adult patients receiving home parenteral nutrition: A systematic review.

TL;DR: There may be benefits in using alternative IVLEs rather than pure SO in adults on HPN, but there are currently too few RCTs to reach a firm conclusion.
Journal ArticleDOI

Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: Analysis of 8 clinical studies with selected patient groups on omega-3-enriched medical nutrition.

TL;DR: Findings further support the safe consumption of n-3 LC-PUFAs, even at short-term doses up to 10 g/day of eicosapentaenoic acid + docosahexaenoic Acid (EPA +-DHA) or consumed for up to 52 weeks above 1.5 G/day, in selected vulnerable and sensitive populations such as subjects with gastrointestinal cancer or patients in an ICU.